Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bugge
Diane Bugge, Rockaway, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080248089 | EDIBLE PRODUCTS FOR THE TREATMENT OF NASAL PASSAGES - The present invention relates to oral delivery systems, such as confectionery and chewing gum compositions, and methods for imparting the perception of nasal clearing to a user. In particular, the present invention includes confectionery and chewing gum compositions including a compound selected from 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 3-butenyl isothiocyanate, 3-methylthiopropyl isothiocyanate, and any combinations thereof and methods. The delivery systems promote the perception of nasal clearing in the user. | 10-09-2008 |
Thomas Bugge, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090142794 | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors - The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site. | 06-04-2009 |
Thomas H. Bugge, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100168012 | HUMAN CANCER THERAPY USING ENGINEERED MATRIX METALLOPROTEINASE-ACTIVATED ANTHRAX LETHAL TOXIN THAT TARGETS TUMOR VASCULATUTURE - The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis. | 07-01-2010 |